Assetmark Inc. Acquires 65,808 Shares of IQVIA Holdings Inc. $IQV

Assetmark Inc. boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 127.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 117,261 shares of the medical research company’s stock after purchasing an additional 65,808 shares during the quarter. Assetmark Inc. owned about 0.07% of IQVIA worth $18,479,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its stake in IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after buying an additional 2,537 shares in the last quarter. Mather Group LLC. increased its holdings in shares of IQVIA by 83.5% in the 1st quarter. Mather Group LLC. now owns 769 shares of the medical research company’s stock valued at $136,000 after acquiring an additional 350 shares during the period. Private Trust Co. NA raised its position in shares of IQVIA by 22.4% in the 1st quarter. Private Trust Co. NA now owns 536 shares of the medical research company’s stock worth $94,000 after acquiring an additional 98 shares in the last quarter. Teacher Retirement System of Texas lifted its stake in shares of IQVIA by 201.6% during the 1st quarter. Teacher Retirement System of Texas now owns 32,432 shares of the medical research company’s stock worth $5,718,000 after purchasing an additional 21,679 shares during the last quarter. Finally, Mutual Advisors LLC boosted its position in IQVIA by 85.1% during the first quarter. Mutual Advisors LLC now owns 3,126 shares of the medical research company’s stock valued at $551,000 after purchasing an additional 1,437 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have issued reports on IQV shares. JPMorgan Chase & Co. raised their price target on IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a report on Wednesday. Hsbc Global Res raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. UBS Group raised their price target on shares of IQVIA from $225.00 to $250.00 and gave the stock a “buy” rating in a report on Wednesday. Stifel Nicolaus boosted their price objective on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Barclays raised their target price on IQVIA from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $241.41.

IQVIA Stock Down 0.0%

IQV opened at $216.43 on Friday. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $225.91. The company has a 50-day moving average price of $197.12 and a 200 day moving average price of $173.77. The company has a quick ratio of 0.84, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The company has a market cap of $36.86 billion, a PE ratio of 29.69, a price-to-earnings-growth ratio of 2.43 and a beta of 1.32.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. During the same period last year, the firm posted $2.84 earnings per share. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.